Neil Graham
Director/Board Member chez ASLAN PHARMACEUTICALS LIMITED
Fortune : - $ au 31/03/2024
Profil
Neil Graham is currently an Independent Director at ASLAN Pharmaceuticals Pte Ltd., Allakos, Inc., Aslan Pharmaceuticals Ltd., and Zura Bio Ltd.
He previously worked as a Director-HIV Medical Affairs at Glaxo Wellcome Plc, an Independent Non-Executive Director at Syntara Ltd., and the VP-Strategic Program Direction & Immunology at Regeneron Pharmaceuticals, Inc. He also held positions as the SVP-Program & Portfolio Management at Trimeris, Inc., the Chief Medical Officer & VP-Clinical Development at XTL Biopharmaceuticals Ltd., and the Senior Vice President-Program & Portfolio at Vertex, Inc. Additionally, he was an Associate Professor at Johns Hopkins Bloomberg School of Public Health.
Dr. Graham obtained a doctorate degree from the University of Adelaide.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 28/02/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Neil Graham
| Sociétés | Poste | Début |
|---|---|---|
| ASLAN PHARMACEUTICALS LIMITED | Director/Board Member | 18/02/2021 |
| ZURA BIO LIMITED | Director/Board Member | 01/03/2023 |
| ALLAKOS INC. | Director/Board Member | 30/08/2023 |
ASLAN Pharmaceuticals Pte Ltd.
 ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore. | Director/Board Member | - |
Anciens postes connus de Neil Graham
| Sociétés | Poste | Fin |
|---|---|---|
| SYNTARA LIMITED | Director/Board Member | 03/10/2023 |
Tiziana Life Sciences Ltd. (United Kingdom)
 Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | Chief Tech/Sci/R&D Officer | 18/07/2022 |
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2020 |
| VERTEX, INC. | Corporate Officer/Principal | 01/11/2009 |
Trimeris, Inc.
 Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Corporate Officer/Principal | 01/02/2007 |
Formation de Neil Graham
| University of Adelaide | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 8 |
|---|---|
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| SYNTARA LIMITED | Health Technology |
| XTL BIOPHARMACEUTICALS LTD. | Health Technology |
| VERTEX, INC. | Technology Services |
| ALLAKOS INC. | Health Technology |
| EVELO BIOSCIENCES, INC. | Health Technology |
| ASLAN PHARMACEUTICALS LIMITED | Health Technology |
| ZURA BIO LIMITED | Health Technology |
| Entreprise privées | 4 |
|---|---|
| Glaxo Wellcome Plc | Health Technology |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Health Technology |
ASLAN Pharmaceuticals Pte Ltd.
ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore. | Health Technology |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | Health Technology |
